Monthly Archives: May 2016
First Do No Harm: Is It Safe to Use Immunosuppressants in Inflammatory Bowel Disease Patients With Prior Cancer?
As the inflammatory bowel disease (IBD) population ages and the incidence of elderly-onset IBD increases, the prevalence of elderly IBD will continue to increase.1 In North America, the increase in prevalence of IBD was higher in the elderly population… Continue reading
First Do No Harm: Is It Safe to Use Immunosuppressants in Inflammatory Bowel Disease Patients With Prior Cancer?
As the inflammatory bowel disease (IBD) population ages and the incidence of elderly-onset IBD increases, the prevalence of elderly IBD will continue to increase.1 In North America, the increase in prevalence of IBD was higher in the elderly population… Continue reading
Good News–Bad News: Current Status of GI Cancers
The annual report on cancer (of all types) in the United States is a collaborative effort from the American Cancer Society, Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Associate of Central Cancer Re… Continue reading
Good News–Bad News: Current Status of GI Cancers
The annual report on cancer (of all types) in the United States is a collaborative effort from the American Cancer Society, Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Associate of Central Cancer Re… Continue reading
Toward a Better Drug for Gastroparesis: The Problem With a Moving Target
Gastroparesis, a disorder defined by delayed gastric emptying, and characterized by nausea, vomiting, and other chronic debilitating symptoms that improves little over time, remains among the most challenging gastroenterological conditions to treat.1 W… Continue reading
Toward a Better Drug for Gastroparesis: The Problem With a Moving Target
Gastroparesis, a disorder defined by delayed gastric emptying, and characterized by nausea, vomiting, and other chronic debilitating symptoms that improves little over time, remains among the most challenging gastroenterological conditions to treat.1 W… Continue reading
The Toronto Helicobacter pylori Consensus in Context
Guideline development uses a formal series of steps that are time, resource, and labor intensive to produce recommendations that are likely to be trustworthy.1 The authors of the Toronto Consensus for the Treatment of Helicobacter pylori, published in… Continue reading
The Toronto Helicobacter pylori Consensus in Context
Guideline development uses a formal series of steps that are time, resource, and labor intensive to produce recommendations that are likely to be trustworthy.1 The authors of the Toronto Consensus for the Treatment of Helicobacter pylori, published in… Continue reading
Detectable Drug Levels in Infants Exposed to Biologics: So What?
Two-thirds of patients with active inflammatory bowel disease (IBD) at the time of conception will either continue to suffer active symptoms or worsen.1,2 Therefore, we strive to achieve remission in women of childbearing potential before conception. M… Continue reading
Detectable Drug Levels in Infants Exposed to Biologics: So What?
Two-thirds of patients with active inflammatory bowel disease (IBD) at the time of conception will either continue to suffer active symptoms or worsen.1,2 Therefore, we strive to achieve remission in women of childbearing potential before conception. M… Continue reading